Biogen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Nektar Therapeutics (NKTR) and GE Healthcare Technologies Inc (GEHC)

🏥 Analysts have issued mixed opinions on Biogen, Nektar Therapeutics, and GE Healthcare Technologies Inc within the healthcare sector.

🛑 BTIG analyst Thomas Shrader maintained a Hold rating on Biogen (BIIB), with shares trading at $183.34 last Monday.

⭐ Shrader holds a 4-star analyst rating based on TipRanks, featuring an average return of 8.8% and a 43.3% success rate.

👍 The current consensus on Biogen is Moderate Buy with an average price target of $208.78, implying 16.3% upside potential.

📉 Morgan Stanley maintained a Hold rating on Biogen in a April 10 report, setting a $200.00 price target.

🟢 Julian Harrison from BTIG issued a Buy rating on Nektar Therapeutics (NKTR) with a price target of $178.00.

💰 Harrison is ranked among top 100 analysts with an impressive average return of 47.0% and a 57.3% success rate.

🚀 The analyst consensus for Nektar Therapeutics is Strong Buy, with a price target consensus of $135.25 representing 38.7% upside.

💼 H.C. Wainwright reiterated a Buy rating on Nektar Therapeutics in a report issued on April 6 with a $135.00 price target.

🏭 BTIG analyst Ryan Zimmerman maintained a Buy rating on GE Healthcare Technologies Inc (GEHC) today with a price target of $85.00.

📊 GE Healthcare shares closed last Monday at $74.15, while the current consensus is Moderate Buy with an average price target of $89.50.

⚖️ This implies a 20.9% upside potential for GEHC based on the analyst consensus data available from TipRanks.

Bullish Signals
  • Biogen has a Moderate Buy consensus with an average price target of $208.78, indicating 16.3% upside potential from current levels.
  • Wells upgraded Biogen to Overweight on its pipeline outside Alzheimer's, highlighting positive momentum in non-core therapeutic areas.
  • Biogen is acquiring TJ Biopharma's exclusive rights to felzartamab in China, expanding its international pipeline opportunities.
  • Nektar Therapeutics has a Strong Buy consensus with an average price target of $135.25, representing 38.7% upside from the recent closing price of $100.35.
  • Morgan Stanley and H.C. Wainwright maintain Hold/Buy ratings on Biogen with price targets above $200, reinforcing analyst confidence.
  • BTIG analyst Julian Harrison maintains a Buy rating on Nektar Therapeutics with a price target of $178.00, citing strong fundamentals.
  • Ryan Zimmerman from BTIG maintained a Buy rating on GE Healthcare Technologies Inc with a price target of $85.00, implying 14% upside.
  • GE Healthcare Technologies has a Moderate Buy consensus with an average price target of $89.50, representing 20.9% upside potential.
Risk Factors
  • Analyst BTIG maintained a Hold rating on Biogen, indicating uncertainty about future growth prospects despite some upside potential.
  • Morgan Stanley also issued a Hold rating on Biogen with a price target of $200.00, which falls short of the higher analyst consensus average of $208.78.
  • The article highlights that Wells upgraded Biogen to Overweight only on the pipeline outside Alzheimer's, suggesting potential limitations or risks in the company's primary therapeutic area.
  • Biogen is set to acquire TJ Biopharma's exclusive rights to felzartamab in China, which could dilute shareholder value without guaranteed significant returns from this specific deal.
  • Analyst Ryan Zimmerman has a poor track record with only a 42.8% success rate and an average return of 0.6%, casting doubt on the reliability of his Buy recommendation for GE Healthcare Technologies Inc.
Full Analysis
Analysts have issued mixed opinions regarding three healthcare sector companies, Biogen (BIIB), Nektar Therapeutics (NKTR), and GE Healthcare Technologies Inc (GEHC). On April 22, BTIG analyst Thomas Shrader maintained a Hold rating on Biogen, which closed last Monday at $183.34. The consensus view for the stock is currently a Moderate Buy with an average price target of $208.78, suggesting 16.3% potential upside from current levels. Additionally, Morgan Stanley reiterated a Hold rating on April 10 with a $200.00 price target. Thomas Shrader is noted as a 4-star analyst covering the healthcare sector with an average return of 8.8% and a 43.3% success rate. Meanwhile, analysts remain bullish on Nektar Therapeutics. Julian Harrison from BTIG issued a Buy rating yesterday with a price target of $178.00; shares closed last Monday at $100.35. Harrison is recognized as a top 100 analyst with an impressive average return of 47.0% and a 57.3% success rate. The overall analyst consensus for Nektar Therapeutics is Strong Buy, reflected in a price target consensus of $135.25 representing a 38.7% upside. H.C. Wainwright supported this sentiment by reiterating a Buy rating on April 6 with a $135.00 price target. Regarding GE Healthcare Technologies Inc, BTIG analyst Ryan Zimmerman maintained a Buy rating today and set a price target of $85.00, while shares closed last Monday at $74.15. Zimmerman covers the healthcare sector but carries a 2-star rating with an average return of 0.6% and a 42.8% success rate according to TipRanks.com. The general consensus on GE Healthcare Technologies Inc is Moderate Buy with an average price target of $89.50, implying a 20.9% upside. A separate report from TipRanks via PerPlexity issued on April 7 also upgraded the stock to Buy with a $79.00 price target.